Alkyl and Aryl Transferases
"Alkyl and Aryl Transferases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A somewhat heterogeneous class of enzymes that catalyze the transfer of alkyl or related groups (excluding methyl groups). EC 2.5.
| Descriptor ID |
D019883
|
| MeSH Number(s) |
D08.811.913.225
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Alkyl and Aryl Transferases".
Below are MeSH descriptors whose meaning is more specific than "Alkyl and Aryl Transferases".
This graph shows the total number of publications written about "Alkyl and Aryl Transferases" by people in this website by year, and whether "Alkyl and Aryl Transferases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 4 | 0 | 4 |
| 2000 | 7 | 0 | 7 |
| 2001 | 2 | 2 | 4 |
| 2002 | 2 | 0 | 2 |
| 2003 | 5 | 1 | 6 |
| 2004 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alkyl and Aryl Transferases" by people in Profiles.
-
Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition. Cancer Res. 2004 Nov 15; 64(22):8389-96.
-
Adini I, Rabinovitz I, Sun JF, Prendergast GC, Benjamin LE. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes Dev. 2003 Nov 01; 17(21):2721-32.
-
Cahoon EB, Hall SE, Ripp KG, Ganzke TS, Hitz WD, Coughlan SJ. Metabolic redesign of vitamin E biosynthesis in plants for tocotrienol production and increased antioxidant content. Nat Biotechnol. 2003 Sep; 21(9):1082-7.
-
Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res. 2003 Jul; 9(7):2520-6.
-
DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene. 2003 Jun 05; 22(23):3578-88.
-
Kamasani U, Liu AX, Prendergast GC. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB. Cancer Biol Ther. 2003 May-Jun; 2(3):273-80.
-
Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene. 2003 Feb 27; 22(8):1124-34.
-
van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002 Jun; 1(8):575-83.
-
Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 2002 Jan 15; 62(2):450-8.
-
Prendergast GC, Rane N. Farnesyltransferase inhibitors: mechanism and applications. Expert Opin Investig Drugs. 2001 Dec; 10(12):2105-16.